References
- Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer, 9, S73-81. https://doi.org/10.3816/CBC.2009.s.008
- Andersen JN, Jansen PG, Echwald SM, et al (2004). A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. Faseb J, 18, 8-30. https://doi.org/10.1096/fj.02-1212rev
- Angers-Loustau A, Cote JF, Charest A, et al (1999). Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration, and cytokinesis in fibroblasts. J Cell Biol, 144, 1019-31. https://doi.org/10.1083/jcb.144.5.1019
- Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol, 86, 116-9 (in German).
- Brady-West DC, McGrowder DA (2011). Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 12, 2139-43
- Cao X, Li Y, Luo RZ, et al (2012). Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg, 93, 1674-80. https://doi.org/10.1016/j.athoracsur.2011.12.056
- Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
- Connolly JL (2006). Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. Arch Pathol Lab Med, 130, 287-91.
- Davidson D, Shi X, Zhong MC, et al (2010). The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity, 33, 167-80. https://doi.org/10.1016/j.immuni.2010.08.001
- DeSantis C, Siegel R, Bandi P, et al (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
- Espejo R, Rengifo-Cam W, Schaller MD, et al (2010). PTPPEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells. Am J Physiol Cell Physiol, 299, C454-63. https://doi.org/10.1152/ajpcell.00148.2010
- Friedrichs K, Gluba S, Eidtmann H, et al (1993). Overexpression of p53 and prognosis in breast cancer. Cancer, 72, 3641-7 https://doi.org/10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
- Galgano MT, Hampton GM, Frierson HJ (2006). Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 19, 847-53.
- Garton AJ, Burnham MR, Bouton AH, et al (1997) Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene, 15, 877-85. https://doi.org/10.1038/sj.onc.1201279
- He J, Peng R, Yuan Z, et al (2012). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29, 406-10. https://doi.org/10.1007/s12032-011-9832-0
- Hsu JL, Huang SY, Chow NH, et al (2003). Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem, 75, 6843-52. https://doi.org/10.1021/ac0348625
- Hunter T (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol, 21, 140-6. https://doi.org/10.1016/j.ceb.2009.01.028
- Kaplan HG, Malmgren JA, Atwood M (2009). T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J, 15, 454-60. https://doi.org/10.1111/j.1524-4741.2009.00789.x
- Kaplan HG, Malmgren JA (2008) Impact of triple negative phenotype on breast cancer prognosis. Breast J, 14, 456-63. https://doi.org/10.1111/j.1524-4741.2008.00622.x
- Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol, 37, 1217-26. https://doi.org/10.1016/j.humpath.2006.04.015
- Kwong A, Wong LP, Wong HN, et al (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat, 117, 683-6. https://doi.org/10.1007/s10549-009-0385-2
- Ma KK, Chau WW, Wong CH, et al (2012). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14. https://doi.org/10.7314/APJCP.2012.13.5.2109
- Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. https://doi.org/10.1158/1078-0432.CCR-04-0220
- Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81. https://doi.org/10.1200/JCO.2007.13.1748
- Rhee I, Veillette A (2012). Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol, 13, 439-47. https://doi.org/10.1038/ni.2246
- Streit S, Ruhe JE, Knyazev P, et al (2006). PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet, 170, 48-53. https://doi.org/10.1016/j.cancergencyto.2006.05.013
- Sun T, Aceto N, Meerbrey KL, et al (2011). Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell, 144, 703-18. https://doi.org/10.1016/j.cell.2011.02.003
- Tonks NK (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol, 7, 833-46. https://doi.org/10.1038/nrm2039
- Villa-Moruzzi E (2011). Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst), 34, 101-12. https://doi.org/10.1155/2011/870459
- Westbrook TF, Hu G, Ang XL, et al (2008). SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature, 452, 370-4. https://doi.org/10.1038/nature06780
- Wu M, Wei W, Xiao X, et al (2012). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol, 29, 3240-9. https://doi.org/10.1007/s12032-012-0260-6
- Zheng Y, Yang W, Xia Y, et al (2011). Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylationdependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol, 31, 4258-69. https://doi.org/10.1128/MCB.05547-11
Cited by
- PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker vol.30, pp.3, 2013, https://doi.org/10.1007/s12032-013-0618-4
- The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3176-x
- Potential role of targeted therapies in the treatment of triple-negative breast cancer vol.27, pp.3, 2016, https://doi.org/10.1097/CAD.0000000000000328
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors vol.34, pp.31, 2016, https://doi.org/10.1200/JCO.2014.59.0018
- Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition vol.35, pp.23, 2015, https://doi.org/10.1128/MCB.00741-15
- The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma vol.10, pp.3, 2018, https://doi.org/10.3390/cancers10030082
- Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways vol.32, pp.1, 2018, https://doi.org/10.1096/fj.201700418R
- The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers vol.10, pp.10, 2018, https://doi.org/10.3390/cancers10100346
- Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer vol.24, pp.4, 2018, https://doi.org/10.1038/nm.4507